tiprankstipranks
Advertisement
Advertisement
Denali’s New Pompe Disease Trial Adds Depth to Its Rare Disease Pipeline
PremiumCompany AnnouncementsDenali’s New Pompe Disease Trial Adds Depth to Its Rare Disease Pipeline
20d ago
Denali Monetizes FDA Voucher to Advance CNS Pipeline
Premium
Company Announcements
Denali Monetizes FDA Voucher to Advance CNS Pipeline
1M ago
Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV
Premium
The Fly
Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV
1M ago
Denali Therapeutics: Buy Rating Reiterated as TV Platform and Enzyme Portfolio Drive Long-Term Upside; $42 Price Target Maintained
PremiumRatingsDenali Therapeutics: Buy Rating Reiterated as TV Platform and Enzyme Portfolio Drive Long-Term Upside; $42 Price Target Maintained
2M ago
Denali, Biogen Halt Parkinson’s Trial After Efficacy Failure
Premium
Company Announcements
Denali, Biogen Halt Parkinson’s Trial After Efficacy Failure
2M ago
Denali Therapeutics trading resumes
Premium
The Fly
Denali Therapeutics trading resumes
2M ago
Denali Therapeutics: AVLAYAH Momentum and Pipeline Progress Support Buy Rating, $39 Price Target Maintained
PremiumRatingsDenali Therapeutics: AVLAYAH Momentum and Pipeline Progress Support Buy Rating, $39 Price Target Maintained
2M ago
Denali Therapeutics: Buy Rating on AVLAYAH Launch Momentum and Undervalued Blood–Brain Barrier TV Platform
Premium
Ratings
Denali Therapeutics: Buy Rating on AVLAYAH Launch Momentum and Undervalued Blood–Brain Barrier TV Platform
2M ago
Denali Therapeutics price target lowered to $23 from $25 at Wedbush
Premium
The Fly
Denali Therapeutics price target lowered to $23 from $25 at Wedbush
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100